Since then, the results from further studies have shown that GH therapy can improve VAT, circulating lipid levels, and insulin resistance in adults with obesity and/or diabetes (Johannsson et al., 1997; Nam et al., 2001). Here, GH1 is linked to obesity due to melanocortin 4 receptor deficiency.